Table 3.

Proportion of children with protective antibody by vaccine antigen and number of vaccine doses.

Vaccine antigen	Country/region
	Russia			China			Guatemala			Kazakhstan			South Korea			Overall
	N	%	(95% CI)	N	%	(95% CI)	N	%	(95% CI)	N	%	(95% CI)	N	%	(95% CI)	N	%	(95% CI)
Diphtheria
<3 doses	100	73	(64–82)	32	38	(21–54)	16	75	(48–93)	10	90	(56–100)	11	100	(72–100)	207	69	(62–75)
≥3 doses	131	88	(82–93)a	102	76	(68–85)b	72	94	(86–98)c	40	80	(64–91)	27	96	(81–100)	458	85	(82–89)b
Tetanus
<3 doses	102	83	(76–91)	32	41	(24–58)	16	94	(70–100)	10	90	(56–100)	11	100	(72–100)	209	76	(70–82)
≥3 doses	132	95	(89–98)a	104	90	(85–96)b	72	99	(93–100)	39	95	(83–99)	27	100	(87–100)	461	95	(93–97)b
Polio
<3 doses	81	83	(74–91)	23	74	(52–90)	13	85	(55–98)	7	86	(42–100)	11	100	(72–100)	174	83	(78–89)
≥3 doses	138	97	(93–99)d	108	85	(78–92)	71	90	(81–96)	41	98	(87–100)	25	96	(80–100)	466	93	(90–95)d
Hepatitis B
<3 doses	156	46	(38–54)	60	38	(26–51)	26	42	(23–61)	14	43	(18–71)	9	33	(7–70)	330	42	(37–47)
≥3 doses	85	89	(81–95)b	75	75	(65–85)b	56	88	(76–95)b	32	63	(46–79)	29	62	(44–80)	340	77	(72–81)b
Hib
<3 doses	102	20	(12–27)	68	10	(4–20)	21	81	(58–95)	23	22	(7–44)	15	80	(52–96)	260	27	(22–33)
≥3 doses	0	–		0	–		33	61	(44–77)	0	–		5	100	(48–100)	39	67	(52–81)b
Measles
<1 doses	49	49	(35–63)	16	56	(30–80)	4	50	(7–93)	6	17	(0–64)	2	50	(1–99)	114	58	(49–67)
≥1 doses	99	92	(85–96)b	63	95	(87–99)d	26	100	(87–100)c	14	100	(77–100)d	6	100	(54–100)	268	95	(92–97)b
Mumps
<1 doses	45	33	(20–47)	51	16	(7–29)	3	67	(9–99)	6	17	(0–64)	2	0	(0–84)	143	31	(23–38)
≥1 doses	85	69	(60–79)b	8	38	(9–76)	24	83	(63–95)	13	85	(55–98)a	6	83	(36–100)	178	72	(66–79)b
Rubella
<1 doses	75	40	(29–51)	50	10	(3–22)	2	100	(16–100)	17	0	(0–20)	2	50	(1–99)	188	30	(23–36)
≥1 doses	46	96	(85–99)b	6	50	(12–88)c	22	91	(71–99)	2	100	(16–100)a	6	100	(54–100)	117	94	(88–98)b

^ap < 0.01.

^bp < 0.0001.

^cp < 0.05.

^dp < 0.001.